Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL: Titration of Biologics in Severe Asthma
NCT04648761Phase 4Unknown
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in severe asthma (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Proportion of patients with exacerbations at 1 year. Status: unknown.
02
Conditions
severe asthma
Beyond the preview
Go deeper on NCT04648761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648761.